Notice of Intent to Sole Source: Procurement of CellGenix GMP rh IL-4 Reagent for Cancer Vaccine Clinical Trials
Closed Special Notice Posted
Not the latest version. See the latest pre-solicitation from .
- Solicitation number
- 75N91022Q00169
- Agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Place of performance
- Bethesda, Maryland 20892, United States
Notice details come from SAM.gov. Updated .
Notice text
PLEASE SEE ATTACHED PDF
The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) requires CellGenix GMP rh IL-4 reagent for cancer vaccine clinical trials.
The Office of Acquisitions (OA) plans to procure, on a sole source basis, the IL-4 reagent from CellGenix USA (One New Hampshire Ave. Ste. 125 Portsmouth, NH 03801-2907).
The response close date of this notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 – Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(1); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325414 – Biological Product (except Diagnostic) Manufacturing.
Files
| File | Type | Posted |
|---|---|---|
| 75N91022Q00169_Special Notice.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Sources Sought/Request for Information: Procurement of CellGenix GMP rh IL-4 Reagent for Cancer Vaccine Clinical Trials | Pre-Solicitation | |
| This notice | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity